EUVIMEDEUVIMED entdecken
Open Access

Identification of an Anoikis-associated LncRNA Signature to Predict the Clinical Prognosis and Immune Function of Patients with Endometrial Cancer

Guanxiao Chen, Ting Zhou, Xiaoyu Shen, Wan Shu, Shuyang Yu, Kejun Dong, Piotr Laudański, Klaudia Gutowska, Shuangshuang Cheng, Hongbo Wang

International Journal of Medical Sciences · 07.05.2025 · 22 (10) · 2502-2517

DOI: 10.7150/ijms.107243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Medical Sciences, erschienen am 07.05.2025. Verfasst von Guanxiao Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Anoikis, Endometrial Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Endometrial cancer is a highly heterogeneous malignancy in women with high mortality, and patients diagnosed with advanced endometrial cancer have a poor prognosis. Anoikis is a form of programmed cell death that is important for cancer development and metastasis. Long non-coding RNAs (lncRNAs) are considered critical regulators of gene expression and key players in cancer biology; however, the effects of anoikis-associated lncRNAs on the prognosis and treatment of patients with endometrial cancer remain unclear.

Methods

Using transcriptome sequencing data and clinical information from The Cancer Genome Atlas database, we developed a novel prognostic signature for endometrial cancer based on anoikis-related lncRNAs by combining multivariate regression analysis and least absolute shrinkage and selection operator regression. The signature was validated by receiver operating characteristic (ROC) curve and Kaplan-Meier analyses. After analyzing the relationships between the seven lncRNAs in the signature and tumor progression through gene set enrichment analysis (GSEA), we further explored the differences in immune function and drug sensitivity. Additionally, to investigate the functions of these lncRNAs in the occurrence and development of endometrial cancer, we selected CFAP58-DT to conduct a series of in vitro and in vivo experiments to verify its partial functions.

Results

Seven anoikis-associated lncRNAs (CFAP58-DT, AC004585.1, AC103563.9, AL121895.2, AC004596.1, AC010761.4, and AC087564.1) with prognostic value were identified for signature construction. The analysis showed excellent predictive accuracy of the signature (the largest area under the ROC curve = 0.757). GSEA indicated that these lncRNAs may regulate diverse cellular processes, including intercellular interactions, cell proliferation, differentiation, apoptosis, angiogenesis, glucose and fatty acid metabolism, immune responses, and inflammatory regulation. Furthermore, immune analysis revealed a high likelihood of immune evasion and poor immunotherapy efficacy in high-risk patients. However, there were distinct differences in the immune checkpoints and anticancer drug sensitivity between the two patient groups, which may aid in guiding treatment. Finally, our experiments showed that silencing CFAP58-DT significantly affected cell proliferation, promoted apoptosis, and reduced tumor malignancy.

Conclusion

Our study highlights the significance of anoikis-associated lncRNAs in endometrial cancer progression and their potential as prognostic markers and therapeutic targets. The signature constructed using these lncRNAs may offer new avenues for endometrial cancer treatment and immunotherapy. The function of CFAP58-DT has been validated in vitro and in vivo, consistent with our previous analysis; however, further research into its upstream and downstream mechanisms is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingAnoikisEndometrial NeoplasmsBiomarkers, TumorHumansFemalePrognosisGene Expression Regulation, NeoplasticGene Expression ProfilingCell Line, TumorAnimalsKaplan-Meier EstimateROC CurveMice

Stichwörter der Autor:innen

anoikisendometrial cancerlncRNAsprognosis

Substanzen

RNA, Long NoncodingBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Department of Obstetrics, Gynecology and Gynecological Oncology, Medical University of Warsaw, Poland.
  • Women's Health Research Institute, Calisia University, Kalisz, Poland.
  • OVIklinika Infertility Center, Warsaw, Poland.
  • Clinical Research Center of Cancer Immunotherapy, Hubei, Wuhan, 430022, China.

Zitieren

APA

Chen, G., Zhou, T., Shen, X., Shu, W., Yu, S., Dong, K., Laudański, P., Gutowska, K., Cheng, S., & Wang, H. (2025). Identification of an Anoikis-associated LncRNA Signature to Predict the Clinical Prognosis and Immune Function of Patients with Endometrial Cancer. International Journal of Medical Sciences, 22(10), 2502-2517. https://doi.org/10.7150/ijms.107243

Vancouver

Chen G, Zhou T, Shen X, Shu W, Yu S, Dong K, et al. Identification of an Anoikis-associated LncRNA Signature to Predict the Clinical Prognosis and Immune Function of Patients with Endometrial Cancer. International Journal of Medical Sciences. 2025;22(10):2502-2517. doi:10.7150/ijms.107243

BibTeX
@article{Chen2025,
  author = {Chen, Guanxiao and Zhou, Ting and Shen, Xiaoyu and Shu, Wan and Yu, Shuyang and Dong, Kejun and Laudański, Piotr and Gutowska, Klaudia and Cheng, Shuangshuang and Wang, Hongbo},
  title = {Identification of an Anoikis-associated LncRNA Signature to Predict the Clinical Prognosis and Immune Function of Patients with Endometrial Cancer},
  journal = {International Journal of Medical Sciences},
  year = {2025},
  volume = {22},
  number = {10},
  pages = {2502--2517},
  doi = {10.7150/ijms.107243}
}
Kostenlos starten →